Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer

As poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with the deficiency of DNA double-strand (DSB) break repair by homologous recombination (HR), PARP inhibitors (PARPi) are currently used to treat breast cancers with mutated <i>BRCA</i>1/2 HR factors. Unfortunately, th...

Full description

Bibliographic Details
Main Authors: Camille Franchet, Jean-Sébastien Hoffmann, Florence Dalenc
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
breast cancer
PARP inhibitor
homologous recombination deficiency
resistance
Online Access:https://www.mdpi.com/2072-6694/13/16/4132

Internet

https://www.mdpi.com/2072-6694/13/16/4132

Similar Items